Hépato-Gastro & Oncologie Digestive


Guide pratique de suivi du transplanté hépatique Volume 25, numéro 4, Avril 2018

  • [1] Rapport médical et scientifique de l’Agence de la biomédecine. www.agence-biomedecine.fr/annexes/bilan2016/accueil.htm.
  • [2] Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant : results of the NIDDK long-term follow-up study. Am J Transplant 2010 ; 10 (6) : 1420-1427.
  • [3] Wiesner R.H., Fung J.J. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011;17:S1-9. Suppl. 3
  • [4] Boudjema K., Camus C., Saliba F. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation : a randomized study. Am J Transplant. 2011;11:965-976. 5
  • [5] Collectif. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology. 1997;25:658-663.
  • [6] Demetris A.J., Bellamy C., Hübscher S.G. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology : Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016;16:2816-2835. 10
  • [7] Vivarelli M., La Barba G., Cucchetti A. Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl. 2007;13:651-654. 5
  • [8] Fischer L., Saliba F., Kaiser G.M. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results From a Randomized Multicenter Study. Transplantation. 2015;99:1455-1462. H2304 Study Group
  • [9] Ojo A.O., Held P.J., Port F.K. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
  • [10] Masetti M., Montalti R., Rompianesi G. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252-2262.
  • [11] Watt K.D., Pedersen R.A., Kremers W.K., Heimbach J.K., Sanchez W., Gores G.J. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137:2010-2017. 6
  • [12] Faure S., Herrero A., Jung B. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol. 2012;57:306-312.
  • [13] Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients : prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011 ; 17 (1) : 15-22.
  • [14] Pisano G., Fracanzani A.L., Caccamo L., Donato M.F., Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol. 2016;22:8869-8882.
  • [15] Moon J.I., Barbeito R., Faradji R.N., Gaynor J.J., Tzakis A.G. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation : Long-term follow up. Transplantation. 2006;82:1625-1628.
  • [16] Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601-2614.
  • [17] Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013 ; 19 (1) : 3-26.
  • [18] Herrero J.I. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15:S90-S94. Suppl. 2
  • [19] Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009 ; 9 (10) : 2355-2361.
  • [20] Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl. 2012;18:1154-1170. Banff Working Group on Liver Allograft Pathology